XBiotech Inc. (XBIT) Form 10-Q — Aug 13, 2026
XBiotech reported a Q2 2026 net loss of $6.7 million ($0.22 per share), versus a $1.8 million loss in the year-ago quarter, with the widening driven mainly by a $1.4 million foreign exchange loss and lower interest income. Six-month net loss was roughly flat at $12.2 million versus $12.6 million in the first half of 2025. The pre-revenue biotech posted Q2 R&D expense of $5.3 million (down 1% YoY) and G&A of $0.9 million (down 15%), with prior-year comparisons inflated by former CEO John Simard's $4.0 million bonus and $3.0 million of immediately-vested options granted in March 2025.
Key figures
- Eps
- -$0.22 (Q2 2026) / -$0.40 (H1 2026), basic and diluted
- Net Income
- -$6.7M (Q2 2026) / -$12.2M (H1 2026); prior-year: -$1.8M (Q2 2025) / -$12.6M (H1 2025)
- Total Assets
- 133651000
- Cash Position
- 109528000
- Shares Outstanding
- 30487731
- Ga expense h1 2026
- 1917000
- Ga expense q2 2026
- 850000
- Rnd expense h1 2025
- 16954000
- Rnd expense h1 2026
- 10503000
- Rnd expense q2 2025
- 5336000
- Rnd expense q2 2026
- 5296000
- Shareholders equity
- 128461000
- Employees june 30 2026
- 87
- Interest income q2 2026
- 885000
- Janssen milestones earned
- 0
- Janssen milestones potential
- 600000000
- Options outstanding june 30 2026
- 5380957
- Workforce reduction subsequent to quarter
- Yes
Price after filing
Close on the filing date to close N calendar days later (from $2.33). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.